الفهرس 
Physiochemical properties of vildagliptinOnly 14 pages are availabe for public view
 |  | from | 169 |  |  |
| | | from | 169 | | |
Abstract
Vildagliptin is a strong and selective dipeptidyl peptidase IV (DPP-4) inhibitor. It can be taken orally as a monotherapy or in combination with metformin as an oral hypoglycemic agent to manage type II diabetes. Recently a single dosage combination of vildagliptin and metformin used to manage type II diabetic patients. Since decreasing blood pressure is vital in lowering the risk of developing cardiovascular problems in type II diabetic patients, a combination of anti-diabetic and anti-hypertension drugs is required and widely employed. In vitro and clinical researches have shown that verapamil inhibits P-gp. Meanwhile, new researches on the beneficial effects of verapamil in the treatment of hypertension in diabetic patients have been published. P-gp, an ATP-binding cassette transporter (ABCB1) member, is located on the apical membrane of intestinal enterocytes, where it actively effluxes its substrate drugs back into the intestinal lumen which reduces their oral bioavailability. So it’s necessary to explore how vildagliptin plasma and
issue concentrations alter when co-administered with verapamil.